Payment overview · 2025
General Payments
$251.81
11 reported records · 2 companies
Healthcare provider profile · identity verified
Scott Houser, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CLAYMONT, DE · NPI 1093844771
Verified facts
What the public records show
CMS Open Payments records show Scott Houser, M.D. received $251.81 in general payments during 2025 across 11 reported records.
Vanda Pharmaceuticals Inc. accounted for 92.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $232.17 | 92.2% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.64 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.81 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $232.17 | 10 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $72.03 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Benztropine Mesylate | Benztropine Mesylate | 284 | 24 |
| Gabapentin | Gabapentin | 177 | 18 |
| Olanzapine | Olanzapine | 168 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 11 |
| Haloperidol | Haloperidol | 125 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 121 | 14 |
| Trazodone Hcl | Trazodone Hcl | 116 | 14 |
| Lisinopril | Lisinopril | 102 | 11 |
| Clonazepam | Clonazepam | 101 | suppressed |
| Lamotrigine | Lamotrigine | 101 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | suppressed |
| Mirtazapine | Mirtazapine | 101 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 95 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | suppressed |
| Metformin Hcl | Metformin Hcl | 93 | suppressed |
| Aripiprazole | Aripiprazole | 92 | 11 |
| Omeprazole | Omeprazole | 92 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 81 | 13 |
| Famotidine | Famotidine | 70 | suppressed |
| Topiramate | Topiramate | 70 | suppressed |
| Paliperidone Er | Paliperidone | 67 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 66 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | suppressed |
| Clozapine | Clozapine | 59 | suppressed |
| Risperidone | Risperidone | 56 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 42 | suppressed |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 38 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 37 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 35 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Abilify Maintena | Aripiprazole | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 19 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Aristada | Aripiprazole Lauroxil | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.81 · 11 records | Vanda Pharmaceuticals Inc. | ABILIFY ASIMTUFII, FANAPT, HETLIOZ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error